Literature DB >> 15980754

Usefulness of specific IgG avidity for diagnosis of hepatitis A infection.

Delphine Desbois1, Liliane Grangeot-Keros, Bénédicte Roquebert, Anne-Marie Roque-Afonso, Vincent Mackiewicz, Jean-Dominique Poveda, Elisabeth Dussaix.   

Abstract

AIM: Diagnosis of acute hepatitis A virus (HAV) infection is classically based on the detection of HAV-IgM. Nevertheless, HAV-IgM can be positive for patients with polyclonal stimulation of their immune system (i.e. immune reactivation). To improve the diagnostic yield, an avidity test for HAV-IgG antibodies was developed and tested.
METHODS: Avidity tests were performed in 128 sera: 11 selected samples from patients with past infection, 15 acute hepatitis A, 10 vaccinated subjects and 4 patients with immune reactivation as well as 84 HAV-IgM positive unselected sera, provided by routine laboratories.
RESULTS: Patients with past infection had avidities over 70%, whereas avidities in patients with acute hepatitis A were below 50% during the first month following the onset of symptoms. As expected, patients with immune reactivation had avidities over 70% consistent with past infection. The results obtained for the 84 unselected sera allowed reconsidering the diagnosis of acute hepatitis A for nearly a third of patients.
CONCLUSION: This test could improve the diagnosis of acute hepatitis A infection, particularly in elderly patients.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15980754     DOI: 10.1016/s0399-8320(05)82132-3

Source DB:  PubMed          Journal:  Gastroenterol Clin Biol        ISSN: 0399-8320


  2 in total

Review 1.  Acute hepatitis B virus infection or acute exacerbation of chronic hepatitis B infection: the differential serological diagnosis.

Authors:  R A A Pondé
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-11-18       Impact factor: 3.267

2.  Southern Tunisia: A still high endemicity area for hepatitis A.

Authors:  Houcine Neffatti; Patricia Lebraud; Corinne Hottelet; Jawher Gharbi; Taieb Challouf; Anne-Marie Roque-Afonso
Journal:  PLoS One       Date:  2017-04-20       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.